Engflag
Advertisements

Diclac 75 ID

Quick links to important sections

Diclac 75 ID

Diclac 75 ID_DE
Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Diclac 75 ID

What is Diclac 75 ID? (Overview)

Property Description
Active ingredient Diclofenac sodium
Form Prolonged-release (extended-release) tablet
Route Oral (by mouth)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relieves pain, stiffness, and inflammation
Origin Synthetic chemical derivative

What Type of Medicine is Diclac 75 ID?

Diclac 75 ID is a pharmaceutical product containing the active ingredient diclofenac sodium, which is a substance used for managing discomfort. It is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a group of medications that target the process of inflammation in the body. Diclofenac is clinically recognized for its analgesic and anti-inflammatory properties. This means that, unlike simple painkillers that only provide temporary relief, Diclac 75 ID provides a dual action that addresses both the sensation of pain and the underlying swelling.

Diclac 75 ID Composition and Formulation

The medication is supplied as a prolonged-release tablet for oral administration. The "ID" in the product name is the distinctive feature, signifying this extended-release design. This formulation is engineered to deliver the single active ingredient, diclofenac, slowly and steadily into the body over several hours.

This sustained-action characteristic is a key differentiator from immediate-release forms and is designed to provide stable, long-lasting relief throughout the day or night. Controlled-release formulations like this one help maintain therapeutic levels in the blood, ensuring sustained symptom control.

General Purpose and Benefit of Diclofenac

The primary purpose of Diclac 75 ID is to function as a pain and inflammation reliever. As an NSAID, its therapeutic action involves blocking the enzymes that create inflammatory substances (prostaglandins), thereby reducing the overall inflammatory response. This mechanism results in the general benefit of easing physical symptoms like swelling and stiffness.

Advertisements

What side effects are possible with Diclac 75 ID?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of diclofenac sodium, as classified by regulatory authorities (e.g., FDA and EMA).

Adverse reactions are classified by both frequency and the body system affected (System-Organ Classes or SOCs). Common effects, reported in 1 to 10 out of 100 users, typically involve the Gastrointestinal disorders (e.g., nausea, dyspepsia, abdominal pain) and Nervous system disorders (e.g., headache, dizziness). Increases in liver enzymes are also commonly reported.

Serious Adverse Reactions and Systemic Risks

The regulatory profile identifies Rare (ge 1/10,000 to <1/1,000) and Very Rare (<1/10,000) serious adverse reactions. These include potentially fatal Gastrointestinal hemorrhage, ulceration, or perforation. The medicine is also associated with an increased risk of serious Arterial Thrombotic Events, such as Myocardial Infarction (heart attack) and Stroke.

Time- and dose-related patterns are noted; cardiovascular risks may increase with higher doses and long-term use. Conversely, the highest risk for serious skin reactions (e.g., Stevens-Johnson Syndrome) typically appears early in therapy.

Safety Restrictions and Special Populations

Official labeling defines several high-level safety restrictions. The medicine is contraindicated in patients with active gastrointestinal bleeding or ulceration, and in those with severe cardiac, hepatic, or renal failure. Particular caution is noted for older adults, who have an officially documented increased frequency and seriousness of adverse effects, particularly gastrointestinal events. Additionally, use is restricted during the third trimester of pregnancy.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents require that immediate medical help must be sought for any suspected overdose of diclofenac sodium, the active ingredient in Diclac 75 ID.

Documented Manifestations and Severe Outcomes

Category Official Regulatory Statement
Documented Manifestations Symptoms may include nausea, vomiting (potentially with blood), diarrhea, stomach pain, headache, dizziness, drowsiness, confusion, and Tinnitus (ringing in the ears).
Life-Threatening Outcomes Overdose can lead to severe, sometimes fatal, complications. These include gastrointestinal perforation, ulceration, severe kidney damage potentially requiring dialysis, and seizures or coma in very severe cases.

Emergency Action and Treatment

Immediate medical attention is required for any suspected overdose. Additionally, patients experiencing signs of serious cardiovascular events, such as chest pain, shortness of breath, sudden weakness, or any signs of internal bleeding (e.g., bloody stools) must seek emergency help immediately.

There is no specific antidote known for diclofenac overdose. Treatment, as described in regulatory documents, is symptomatic and supportive, focusing on managing the clinical condition. Procedures that may be initiated in a clinical setting include the use of activated charcoal and monitoring of vital signs and organ function via laboratory tests and ECG.

Population Considerations

Official labeling notes that elderly patients are at greater risk for serious gastrointestinal adverse events, and overdose severity risk is increased in patients with pre-existing asthma or impaired renal or hepatic function.

Advertisements

Therapeutic Uses of Diclac 75 ID

Main Uses and Therapeutic Benefits of Diclac 75 ID

Diclac 75 ID is commonly used in situations involving certain distressing symptoms related to pain and inflammation, and generally supports improved comfort during periods of heightened symptoms. The medication is relevant when supportive symptom management is appropriate for easing the discomfort and swelling of inflammatory conditions.

The drug is applied across domains where short-term symptomatic assistance is needed, including the persistent physical discomfort of chronic inflammatory conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. It is also used in acute settings to address distressing manifestations associated with conditions such as Gouty Arthritis flares, post-traumatic pain, and severe primary dysmenorrhea (menstrual pain).

The formulation generally contributes to improved comfort during periods of heightened symptoms, and may assist with maintaining functional stability when symptoms interfere with routine activities.

"This symptomatic relief helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load."

Quick Fact: Relief for Inflammatory Symptoms
Diclac 75 ID is applied across therapeutic domains characterized by inflammatory or irritative states where additional symptomatic support is needed.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Diclac 75 ID — Official Regulatory Information

Populations for Whom Use is Contraindicated

The following groups must not use Diclac 75 ID, as risks are officially deemed unacceptable by regulatory authorities (Absolute Contraindication):

Contraindicated Population Specific Conditions
Cardiovascular/Vascular Disease Established congestive heart failure (NYHA Class II-IV), ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease. Also contraindicated for perioperative pain in the setting of CABG surgery.
Gastrointestinal Disease Active, or a history of recurrent peptic ulcers, gastrointestinal bleeding, or perforation.
Organ Failure Severe hepatic failure or severe renal failure.
Allergy History Known hypersensitivity to diclofenac or any NSAID that causes asthma, urticaria, or allergic-type reactions.

Eligibility and Conditional Use

Population Group Official Regulatory Status
Adults (General) Use is allowed and indicated for pain and inflammation relief.
Children and Adolescents (Under 18) Not suitable/Not recommended due to the dosage strength of the 75 mg prolonged-release tablet; safety and efficacy are not established for this group.
Older Adults (Geriatric) Use with particular caution is advised; the lowest effective dosage is recommended, especially for frail patients.
Pregnancy/Lactation Contraindicated during the third trimester of pregnancy. Use during the first and second trimesters and during breastfeeding is not recommended.
Organ Impairment (Moderate) Caution is advised when administering to patients with mild to moderate renal or hepatic impairment.
Advertisements

What should I know about interactions with other medicines?

The official regulatory profile for Diclac 75 ID (diclofenac sodium) is structured around pharmacodynamic risks and pharmacokinetic alterations. Co-administration with other systemic NSAIDs (including COX-2 selective inhibitors) and use for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery are formal restrictions documented in labeling.

Pharmacodynamic and Contraindicated Combinations

Concurrent use with anticoagulants (e.g., warfarin) and antiplatelet agents carries a documented increased risk of serious gastrointestinal bleeding. Diclofenac may reduce the antihypertensive and natriuretic effects of diuretics and ACE inhibitors/ARBs, and these combinations increase the risk of renal function deterioration. The combination with drugs such as SSRIs or corticosteroids also increases the official risk of gastrointestinal ulceration or bleeding.

Pharmacokinetic and Exposure-Altering Effects

Diclofenac clearance is partially dependent on the CYP2C9 enzyme pathway. Co-administration with potent CYP2C9 inhibitors (e.g., voriconazole) results in a documented increase in diclofenac plasma concentration and exposure. Diclofenac can also increase the plasma concentrations of certain co-administered drugs, including Lithium and Digoxin, requiring official regulatory guidance for serum level monitoring. Additionally, the combination with Methotrexate increases its plasma levels, particularly when administered within 24 hours of each other. Elderly patients are noted as having a greater risk for serious adverse events when diclofenac is combined with interacting medicines.

Advertisements

Mechanism of Action

Key Mechanism: Inhibition of COX Enzymes

The fundamental mechanism involves the active ingredient, diclofenac, acting as a reversible inhibitor of the Cyclooxygenase (COX) enzymes, specifically targeting both the constitutive COX-1 and the inducible COX-2 isoforms. By blocking these enzymes, the drug engages a mechanism that suppresses the biological synthesis of chemical mediators involved in nociceptive signaling and inflammatory pathways.

Dampening the Prostaglandin Synthesis Pathway

Inhibition of the COX enzymes directly interrupts the arachidonic acid cascade, leading to a profound reduction in the systemic levels of prostaglandins (such as PGE2). These prostaglandins are regulators involved in nociceptive signaling and the physiological processes of inflammation, including changes in local vascular tone. This reduction of mediators causes an alteration in the chemical environment within the targeted pathways in both peripheral tissues and the central nervous system.

Modulating Nociceptor Sensitization

The physiological consequence of reduced prostaglandin levels is the diminished sensitization of peripheral nociceptors (afferent nerve endings). Prostaglandins typically lower the activation threshold of these nerves, making them hypersensitive to stimuli. By limiting this chemical sensitization, the mechanism causes a decrease in the firing threshold of nociceptors and attenuates prostaglandin-mediated physiological responses.

Advertisements

Dosage and Administration Information

How to Use Diclac 75 ID

The administration of Diclac 75 ID, a prolonged-release tablet containing diclofenac sodium, is based on standard clinical parameters to ensure correct usage and adherence to the lowest effective dosage for the shortest duration necessary.

Official Administration Guidelines

The medicine is designed exclusively for oral administration (taken by mouth). The characteristic prolonged-release formulation is engineered to release the active ingredient slowly; consequently, the tablet must be swallowed whole with liquid and must not be divided, crushed, or chewed.

Category Official Instruction
Route of Administration Oral (by mouth)
Dosing Range The total daily dose generally ranges from 75 mg to 150 mg. The maximum daily dose of diclofenac is strictly limited to 150 mg.
Frequency Pattern Typically taken once daily or in divided doses (e.g., 75 mg twice daily) to reach the necessary total dose.
Timing Principle Recommended to be taken with or after food. For symptoms most pronounced at night or in the morning, the tablet is often taken in the evening.

Population-Specific Use and Duration

Standard protocols emphasize that the medication should be used for the shortest duration possible, utilizing the lowest effective dose to manage symptoms. For older adults, while no specific dose reduction is typically mandated, clinical guidelines suggest using the lowest effective dosage, particularly for frail patients. The prolonged-release form of 75 mg is not recommended for the pediatric population. If a dose is missed, patients are instructed not to take a double dose to compensate.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diclac 75 ID

Evidence for Use in Chronic Joint Conditions (Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis)

Diclofenac was studied for use in conditions marked by functional limitations and periods of heightened symptoms, such as Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). Research primarily involved short- to intermediate-term Randomized Controlled Trials (RCTs), where researchers examined how symptoms evolved in the observed populations in adult populations. The research examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level, with measurements often applied in studies examining symptom intensity or variability.

In these studies, researchers monitored changes in outcomes related to physical discomfort, stiffness, and outcomes reflecting daily functioning. Findings describe patterns observed in the studies, contributing to the understanding of outcomes reflecting daily functioning. The evidence contributes to the broader evidence landscape related to symptom patterns in conditions characterized by functional limitations.

Evidence for Use in Short-Term Inflammatory Pain (Including Primary Dysmenorrhea)

Diclofenac was studied for use in conditions involving periods of heightened symptoms or conditions associated with acute or disruptive episodes, such as short-term pain or primary dysmenorrhea (menstrual pain). Research examined short-term, single-dose, or short-cycle trials in adult populations experiencing temporary physiological imbalance.

In these trials, studies monitored outcomes describing episodic or acute changes, focusing on the time to onset and magnitude of outcomes related to physical discomfort over short assessment periods. Findings indicate patterns related to outcomes describing episodic or acute changes observed during the study period.

What is Still Uncertain About Diclac 75 ID Research

Evidence is limited regarding the sustained symptomatic response beyond the typical trial periods of four to twelve weeks. Research provides insight into short-term changes, but the long-term effects are not fully established regarding maintaining these reported patterns of symptom relief.

The research explored symptomatic effects, and there is limited information for long-term outcomes regarding the impact on structural or physiological changes in conditions like OA and RA. Comparative evidence is limited across all available formulations of diclofenac, and subgroup findings are uncertain, meaning certainty remains low in certain contexts. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Efficacy of ultramicronised diclofenac in patients with osteoarthritis – systematic review with network meta-analysis
  2. Diclofenac Oral (MedlinePlus Drug Information)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Diclac 75 ID (FAQ)

Q: What is the difference between Diclac 75 ID and regular Diclac tablets?

A: Official product information describes Diclac 75 ID as a prolonged-release tablet. This formulation is specially engineered to release the active ingredient, diclofenac, slowly and steadily over several hours. This is the primary formulation difference compared to immediate-release or 'regular' forms of the medication.

Q: How quickly does Diclac 75 ID usually start to relieve discomfort?

A: As this is a prolonged-release medicine, it is formulated to maintain consistent therapeutic levels over a sustained period. The focus in regulatory documents is typically on maintaining a stable therapeutic level for sustained relief.

Q: What is the typical duration of the effects of one Diclac 75 ID tablet?

A: This prolonged-release formulation is designed to provide sustained action. Regulatory texts often describe the dosage frequency as typically once daily to allow for long-lasting relief throughout the day or night.

Q: Is Diclac 75 ID a drug that can cause drowsiness?

A: Official side effect listings note that effects on the central nervous system, such as dizziness and headache, are common concerns. Regulatory data confirms that drowsiness has been reported, however, the frequency of this effect is often unclassified or rare in official reports.

Q: Are there risks associated with using Diclac 75 ID for an extended time?

A: Official regulatory warnings advise that both cardiovascular risks and the risk of serious gastrointestinal events may increase with the dose and the duration of exposure (long-term use). Official guidance emphasizes using the lowest effective dosage for the shortest duration necessary.

Q: Is it safe to use Diclac 75 ID if I am taking over-the-counter supplements?

A: Regulatory guidance advises patients to inform their healthcare providers of all other products they are using, which includes over-the-counter medications, vitamins, and herbal supplements. This is due to the potential for interactions that may affect how the medicine works or increase the risk of side effects.

Q: Is Diclac 75 ID considered safe for women who are breastfeeding?

A: According to official regulatory documents, use of Diclac 75 ID during breastfeeding is not recommended. This caution is based on the finding that diclofenac, the active ingredient, is known to pass into breast milk in small amounts.

Q: Does Diclac 75 ID help with swelling as well as pain?

A: Yes. Diclac 75 ID is categorized as a Nonsteroidal Anti-inflammatory Drug (NSAID). Official therapeutic indications confirm its purpose is for the relief of pain, stiffness, and inflammation (swelling) associated with various conditions.

Q: Are there reports of Diclac 75 ID affecting sleep patterns?

A: Official adverse reaction lists for diclofenac, under Nervous System disorders, include reports of effects on sleep. Specifically, insomnia (difficulty sleeping) has been reported in studies. This effect is generally reported with an unclassified or rare frequency.

Q: Is Diclac 75 ID the same type of drug as ibuprofen?

A: Both the active ingredient in Diclac 75 ID (diclofenac) and ibuprofen are classified in regulatory documents as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), meaning they belong to the same pharmacological group.

Q: Can Diclac 75 ID be used for headache or migraine symptoms?

A: Diclofenac formulations are indicated for the treatment of painful conditions resulting from trauma and inflammation. Some diclofenac formulations are indicated for acute migraines, though use for specific conditions is determined by the prescribing information.

Q: Are there any known issues with taking Diclac 75 ID with food?

A: Official guidance recommends taking the tablets with or after food. Taking the medicine without food, particularly on an empty stomach, may increase the potential for common gastrointestinal side effects like stomach upset and dyspepsia.

Q: Is a stomach upset a frequent concern when using Diclac 75 ID?

A: Yes, regulatory documents classify Gastrointestinal disorders as Common effects, meaning they affect 1 to 10 out of every 100 users. These disorders include nausea, abdominal pain, and dyspepsia, which are commonly described as stomach upset.

Q: What age group is generally restricted from using Diclac 75 ID?

A: The prolonged-release form of Diclac 75 ID is not recommended for use in children and adolescents. Official regulatory guidance states that the safety and efficacy for this specific dosage strength have not been established in the pediatric population (under 18 years).

Q: Can Diclac 75 ID be used by people with high blood pressure?

A: Regulatory warnings indicate that diclofenac can cause new hypertension (high blood pressure) or worsen existing hypertension. Official documents advise caution, and monitoring of blood pressure is typically recommended when the drug is used.

Q: Is there a safety concern about using Diclac 75 ID for patients with kidney issues?

A: Yes. Regulatory documents contraindicate the use of this medicine in patients with severe renal failure. Caution is specifically advised for those with pre-existing kidney impairment, as use may hasten the progression of renal dysfunction.

Q: Is the diclofenac in Diclac 75 ID the same as diclofenac in topical gels?

A: Both the tablet and topical gels contain the same active ingredient, diclofenac. The key distinction is the route of administration; Diclac 75 ID is absorbed into the bloodstream systemically, while topical gels result in a significantly lower level of absorption into the bloodstream.

Q: Does Diclac 75 ID affect how alcohol is processed in the body?

A: While not a direct pharmacokinetic interaction, official regulatory guidance warns that concurrent consumption of alcohol may increase the risk of gastrointestinal side effects. This includes the risk of serious stomach bleeding associated with the use of diclofenac.

Q: Can Diclac 75 ID cause changes to my skin or trigger rashes?

A: Yes, official documents list skin rash and urticaria (hives) as possible adverse reactions. Regulatory warnings also note the possibility of rare but serious skin reactions (e.g., Stevens-Johnson Syndrome), which typically appear early in therapy.

Q: Is Diclac 75 ID used for nerve-related pain relief?

A: The mechanism of action involves dampening the pain signals carried by nerve endings, which is related to its general use for various types of pain.

Q: Is Diclac 75 ID used to reduce a fever?

A: Diclofenac is classified in regulatory pharmacodynamics sections as a Nonsteroidal Anti-inflammatory Drug (NSAID) that exhibits anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing) activities.

Q: What is the purpose of the enteric coating (if applicable) on some diclofenac tablets?

A: The enteric coating used on some diclofenac tablets is typically intended to protect the drug from being broken down by stomach acid. The coating is intended to protect the drug from being broken down by stomach acid, which may contribute to reducing the risk of gastrointestinal irritation.

Q: Can taking Diclac 75 ID affect the results of blood tests?

A: Official adverse reaction documents commonly report a rise in liver enzyme values during treatment with diclofenac, which would be visible in standard blood tests. Monitoring of renal function, also assessed through blood tests, is also advised by regulatory guidance.

Q: Is it possible to be allergic to Diclac 75 ID?

A: Yes, it is possible. The medicine is contraindicated in patients with a known hypersensitivity (allergy) to the active substance, diclofenac, or to any of the components used in the tablet's formulation.

Q: Does Diclac 75 ID contain lactose or gluten?

A: Official excipient lists for the tablet commonly show the presence of lactose monohydrate. Regarding this component, official labeling notes that patients with rare hereditary problems like galactose intolerance should generally avoid the product. Gluten is not typically noted as a component risk.

Q: What are the signs of a serious, but rare, side effect from Diclac 75 ID?

A: Regulatory documents describe certain warning signs that may necessitate immediate attention, such as bloody or black stools, vomiting blood, chest pain, unexplained swelling, shortness of breath, or slurred speech.

Q: What other names or brands are often confused with Diclac 75 ID?

A: The active ingredient, diclofenac, is available under multiple brands globally. The prolonged-release form of the drug is frequently referenced by the official brand name Voltaren-XR in some regulatory documents.

Advertisements

How should Diclac 75 ID be stored and disposed of?

Storage and Disposal of Diclac 75 ID

Official regulatory documents mandate specific conditions for storing and disposing of Diclac 75 ID (diclofenac sodium prolonged-release tablets) to maintain product stability and ensure public safety.

Mandatory Storage Conditions

Item Requirement
Temperature Store at a temperature not exceeding 25°C (77°F).
Protection Must be protected from light and moisture and kept from freezing.
Packaging Keep the medicine in its original package (blister and carton).

Safety and Disposal

The medicine must be kept out of the sight and reach of children to prevent accidental ingestion. For disposal, unused or expired Diclac 75 ID must not be thrown away with household waste or down the drain. Disposal must follow local requirements, and patients should consult a pharmacist for guidance on proper procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Diclac 75 ID found in:

A-Z Index: